Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Net Income

Bottom-line profit after all expenses, interest, and taxes.

Aurora Cannabis Inc.NASDAQ: ACB

Net Income · Q4 FY2026 · quarter ended Mar 2026

Net income remains negative

Q4 FY2026 net income was -CA$57.04M, compared with -CA$24.56M a year earlier. Trailing-twelve-month net income was -CA$75.03M.

Context

  • Net income amounted to 38.0% of revenue in FY2026, up 37.5 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -CA$26.79M (+78.1%) for the fiscal year ending Mar 2027, a step up from the -7772.8% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$57.04M-3234.3% QoQ
Last fiscal yearMar 2026
-CA$122.07M-7772.8% YoY
LTMMar 2026
-CA$75.03M-4815.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-132.3%-138.3%-6.0 pp
1 year-7772.8%+78.1%+7850.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the income statement

Latest · FY2026
(122.07M) CAD
Year-over-year change
-7772.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4815.8% is the lowest of 10, against a peer median of +26.3%.
  • Net income amounts to 24.1% of revenue for ACB, versus a peer median of 34.7%.
ACB Competitors
Net Income for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$102.18M USD+415.9%-48.4%28.3%
LFMDLifeMD, Inc.LTM Mar 2026-$16.25M USD-58.5%—7.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.17M USD+26.3%—41.1%
OGIOrganigram Global Inc.LTM Mar 2026-CA$25.23M CAD-249.4%—9.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$34.09M USD——25.2%
HITIHigh Tide Inc.LTM Apr 2026-CA$44.03M CAD-355.0%—6.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
ACBAurora Cannabis Inc.LTM Mar 2026-CA$75.03M CAD-4815.8%—24.1%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
CGCCanopy Growth CorporationLTM Mar 2026-CA$366.64M CAD+38.7%—117.4%
Peer median (excluding ACB) —+26.3%-48.4%34.7%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.